(Q27853001)

English

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

scientific article published in June 2014

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

PubMed publication ID

13 November 2016

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial (English)

1 reference

PubMed publication ID

13 November 2016

phase III clinical trial

0 references

ado-trastuzumab emtansine

0 references

Her2-receptor positive breast cancer

0 references

1 reference

based on heuristic

inferred from title

author name string

Ian E Krop

1

0 references

Sung-Bae Kim

2

0 references

Antonio González-Martín

3

0 references

Patricia M LoRusso

4

0 references

Jean-Marc Ferrero

5

0 references

Melanie Smitt

6

0 references

Ron Yu

7

0 references

Abraham C F Leung

8

0 references

Hans Wildiers

9

0 references

publication date

June 2014

0 references

Lancet Oncology Commission

0 references

15

0 references

7

0 references

689-99

0 references

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab emtansine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of Blinded Independent Central Review of Tumor Progression in Oncology Clinical Trials: A Meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970178-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70178-0

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27853001&oldid=1561181063"